Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > oh dear

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Jun 05, 2023 9:43am

119 Views

Post# 35480162

RE:RE:oh dear

Maybe not Noteable.. but they will run out of time to get such a combination into Phase III before the patent expires..

if this news were being well recieved, we would see an appreciation of pps... it's been seen as yet another nothing burger..

So, still no partner, which means NO phase III, no mention of biomarkers, no accelerated approval... just more... wait and see, and we hope to get back to all you faithful dreamers in another 6 months...

Just remind me what ONCY has really achieved in the last 5 years besides a 7 fold dilution in stock.

still reckon this is worth 10 Billion..???

<< Previous

Bullboard Posts

Next >>

AtkinsRéalis supports Poland’s nuclear power endeavour